^
    Apply
    Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (NCT00740805)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    08/18/2008
    Primary completion :
    09/03/2021
    Completion :
    10/22/2025
    HER-2 • ER • PGR • BRCA1 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888) • cyclophosphamide intravenous
    A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer (BROCADE3) (NCT02163694)
    Phase 3
    AbbVie
    Completed
    Last update posted :
    02/19/2025
    Initiation :
    04/08/2014
    Primary completion :
    04/05/2019
    Completion :
    01/25/2024
    HER-2 • BRCA1 • BRCA2
    |
    HER-2 negative
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors (NCT02631733)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/10/2025
    Initiation :
    05/31/2017
    Primary completion :
    11/21/2019
    Completion :
    05/24/2023
    BRCA
    |
    BRCA mutation
    |
    veliparib (ABT-888) • Onivyde (nanoliposomal irinotecan)
    FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (S1513) (NCT02890355)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/01/2016
    Primary completion :
    05/01/2019
    Completion :
    03/05/2025
    BRCA1 • BRCA2 • HRD • CEACAM5
    |
    HRD
    |
    5-fluorouracil • irinotecan • veliparib (ABT-888) • leucovorin calcium • fluorouracil topical
    Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases (NCT02595905)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    09/15/2016
    Primary completion :
    03/15/2025
    Completion :
    03/15/2025
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    cisplatin • veliparib (ABT-888)
    Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (NCT01386385)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    06/20/2011
    Primary completion :
    05/26/2019
    Completion :
    12/31/2025
    ERCC1 • XRCC1
    |
    ERCC1 expression
    |
    carboplatin • paclitaxel • veliparib (ABT-888)
    Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (ACNS1721) (NCT03581292)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/06/2018
    Primary completion :
    03/31/2023
    Completion :
    10/16/2025
    BRAF
    |
    IDH wild-type
    |
    temozolomide • veliparib (ABT-888)
    Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (NCT01434316)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    11/11/2011
    Primary completion :
    03/28/2023
    Completion :
    08/02/2025
    BRCA1 • BRCA2 • BRCA • RAD51
    |
    BRCA mutation
    |
    veliparib (ABT-888) • dinaciclib (MK-7965)
    Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer (NCT02158507)
    Phase N/A
    University of Alabama at Birmingham
    Completed
    Last update posted :
    02/03/2025
    Initiation :
    09/04/2014
    Primary completion :
    07/22/2021
    Completion :
    07/22/2021
    HER-2 • PGR • BRCA1 • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    lapatinib • veliparib (ABT-888)
    I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY 2) (NCT01042379)
    Phase 2
    QuantumLeap Healthcare Collaborative
    Recruiting
    Last update posted :
    10/22/2024
    Initiation :
    03/01/2010
    Primary completion :
    12/01/2030
    Completion :
    12/01/2031
    HER-2 • ER
    |
    ER positive • ER negative
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1
    Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma (NCT03061188)
    Phase 1
    Northwestern University
    Completed
    Last update posted :
    06/12/2024
    Initiation :
    05/23/2017
    Primary completion :
    03/11/2018
    Completion :
    08/04/2020
    BRCA1 • BRCA2 • MSI • POLE • BAP1 • CDK12 • ERCC2 • CHEK2 • RAD51 • FANCA • POLD1 • RAD50 • CHEK1 • BARD1 • NBN • EMSY • FANCD2 • FANCE • PRKDC • FANCC
    |
    MSI-H/dMMR • RAD50 mutation
    |
    Opdivo (nivolumab) • veliparib (ABT-888)
    Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (A071102) (NCT02152982)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    12/15/2014
    Primary completion :
    12/01/2021
    Completion :
    12/15/2024
    MGMT
    |
    temozolomide • veliparib (ABT-888)
    Response to PARP Inhibitor Predicted by the RAD51 Assay (REPAIR) (NCT03044795)
    Phase 2
    University Medical Center Groningen
    Withdrawn
    Last update posted :
    05/03/2024
    Initiation :
    11/01/2019
    Primary completion :
    11/01/2020
    Completion :
    11/01/2020
    ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    veliparib (ABT-888)
    Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (NCT01351909)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    05/02/2011
    Primary completion :
    11/25/2016
    Completion :
    03/07/2025
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA1 mutation • HER-2 negative • PGR positive • BRCA mutation • PARP1 expression
    |
    cyclophosphamide • veliparib (ABT-888)
    Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer (NCT01585805)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    05/15/2012
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    BRCA1 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • BRCA mutation
    |
    cisplatin • gemcitabine • veliparib (ABT-888) • liposomal gemcitabine (FF-10832)
    Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer (NCT01149083)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/06/2024
    Initiation :
    06/30/2010
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    BRCA
    |
    BRCA mutation
    |
    carboplatin • veliparib (ABT-888)
    Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer (NCT01012817)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    03/05/2024
    Initiation :
    11/03/2009
    Primary completion :
    01/13/2019
    Completion :
    08/30/2024
    BRCA1 • BRCA2
    |
    BRCA mutation
    |
    veliparib (ABT-888) • topotecan
    ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer (NCT01009788)
    Phase 2
    Steven J Isakoff, MD, PhD
    Active, not recruiting
    Last update posted :
    11/14/2023
    Initiation :
    11/01/2009
    Primary completion :
    05/01/2021
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • BRCA
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation
    |
    temozolomide • veliparib (ABT-888)
    MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations (NCT01827384)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/29/2023
    Initiation :
    01/07/2014
    Primary completion :
    06/19/2021
    Completion :
    10/08/2021
    BRCA
    |
    BRCA mutation
    |
    Mekinist (trametinib) • carboplatin • everolimus • temozolomide • adavosertib (AZD1775) • veliparib (ABT-888)
    Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery (NCT00576654)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2023
    Initiation :
    12/05/2007
    Primary completion :
    06/30/2023
    Completion :
    06/30/2023
    BRCA
    |
    irinotecan • veliparib (ABT-888)
    Expanded Access to Veliparib (NCT03123211)
    Phase N/A
    AbbVie
    No Longer Available
    Last update posted :
    05/24/2022
    BRCA
    |
    veliparib (ABT-888)
    Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors (NCT02723864)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/08/2022
    Initiation :
    08/09/2017
    Primary completion :
    12/15/2020
    Completion :
    12/31/2021
    RAD51 • NBN
    |
    cisplatin • veliparib (ABT-888) • berzosertib (M6620)
    Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer (NCT01506609)
    Phase 2
    AbbVie
    Completed
    Last update posted :
    10/25/2021
    Initiation :
    01/23/2012
    Primary completion :
    12/13/2018
    Completion :
    09/02/2020
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    carboplatin • paclitaxel • temozolomide • veliparib (ABT-888)
    Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer (NCT02985658)
    Phase N/A
    University of Washington
    No Longer Available
    Last update posted :
    07/21/2021
    HER-2 • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cisplatin • veliparib (ABT-888) • vinorelbine tartrate
    Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer (GCTSK004) (NCT02860819)
    Phase 2
    National Cancer Institute, Slovakia
    Completed
    Last update posted :
    03/03/2021
    Initiation :
    08/01/2016
    Primary completion :
    11/30/2020
    Completion :
    02/15/2021
    AFP
    |
    carboplatin • gemcitabine • veliparib (ABT-888)
    A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (BrighTNess) (NCT02032277)
    Phase 3
    AbbVie
    Completed
    Last update posted :
    01/20/2021
    Initiation :
    04/02/2014
    Primary completion :
    03/18/2016
    Completion :
    11/12/2020
    HER-2 • ER • PGR • BRCA
    |
    HER-2 negative • BRCA mutation
    |
    carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • veliparib (ABT-888)
    ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer (NCT01489865)
    Phase 1/2
    Georgetown University
    Unknown status
    Last update posted :
    03/03/2020
    Initiation :
    02/01/2011
    Primary completion :
    12/01/2020
    Completion :
    12/01/2020
    BRCA1 • BRCA2 • BRCA
    |
    BRCA1 mutation • PALB2 mutation • BRCA mutation
    |
    5-fluorouracil • oxaliplatin • veliparib (ABT-888) • leucovorin calcium
    A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors (NCT00994071)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/09/2019
    Initiation :
    09/22/2009
    Completion :
    03/19/2013
    AFP
    |
    temozolomide • veliparib (ABT-888)
    Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer (NCT01818063)
    Phase 2
    Sidney Kimmel Cancer Center at Thomas Jefferson...
    Completed
    Last update posted :
    10/28/2019
    Initiation :
    04/25/2013
    Primary completion :
    03/01/2015
    Completion :
    12/10/2018
    HER-2 • ER • PGR • UGT1A1
    |
    HER-2 negative • ER negative • UGT1A1*1*1 • PGR negative
    |
    carboplatin • albumin-bound paclitaxel • cyclophosphamide • veliparib (ABT-888) • pegylated liposomal doxorubicin
    Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT01540565)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/23/2019
    Initiation :
    04/09/2012
    Primary completion :
    01/27/2018
    Completion :
    01/27/2018
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cisplatin • veliparib (ABT-888)
    Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (NCT01459380)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/22/2019
    Initiation :
    10/11/2011
    Primary completion :
    06/08/2016
    Completion :
    02/11/2017
    BRCA • MUC16
    |
    Avastin (bevacizumab) • carboplatin • veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy (NCT00892736)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/29/2018
    Initiation :
    04/20/2009
    Primary completion :
    05/19/2017
    Completion :
    05/19/2017
    HER-2 • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • BRCA mutation • BRCA2 expression • PGR negative
    |
    veliparib (ABT-888)
    A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer (NCT01113957)
    Phase 2
    AbbVie (prior sponsor, Abbott)
    Completed
    Last update posted :
    06/06/2018
    Initiation :
    03/01/2010
    Primary completion :
    06/01/2013
    Completion :
    06/01/2013
    MUC16
    |
    temozolomide • veliparib (ABT-888) • pegylated liposomal doxorubicin
    A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors (NCT02210663)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    05/07/2018
    Initiation :
    07/01/2014
    Primary completion :
    01/01/2016
    Completion :
    07/01/2016
    BRCA
    |
    BRCA mutation
    |
    veliparib (ABT-888)
    Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer (NCT01251874)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/23/2018
    Initiation :
    11/16/2010
    Primary completion :
    04/12/2017
    Completion :
    04/12/2017
    HER-2 • ER • PGR • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive
    |
    carboplatin • veliparib (ABT-888)
    Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer (NCT01145430)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    12/22/2017
    Initiation :
    06/01/2010
    Primary completion :
    05/23/2017
    HER-2 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    veliparib (ABT-888) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
    A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients (NCT00526617)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    11/21/2017
    Initiation :
    08/01/2007
    Primary completion :
    06/01/2010
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA mutation
    |
    temozolomide • veliparib (ABT-888)
    Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer (NCT01264432)
    Phase 1
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    11/21/2017
    Initiation :
    01/01/2011
    Primary completion :
    11/15/2016
    Completion :
    11/15/2016
    BRCA1 • MSI • BRCA
    |
    veliparib (ABT-888)
    A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors (NCT01853306)
    Phase 1
    AbbVie
    Completed
    Last update posted :
    11/21/2017
    Initiation :
    03/18/2013
    Primary completion :
    05/03/2017
    Completion :
    06/29/2017
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    veliparib (ABT-888)
    Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients (NCT03032614)
    Phase 2
    The University of Texas Health Science Center a...
    Withdrawn
    Last update posted :
    10/10/2017
    Initiation :
    09/30/2017
    Primary completion :
    03/31/2019
    Completion :
    04/30/2020
    BRCA1 • BRCA2 • PTEN
    |
    PTEN deletion • High HRD score
    |
    cisplatin • carboplatin • Halaven (eribulin mesylate) • veliparib (ABT-888)
    Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma (NCT01495351)
    Phase 1
    AHS Cancer Control Alberta
    Completed
    Last update posted :
    09/25/2017
    Initiation :
    10/01/2011
    Primary completion :
    02/01/2015
    Completion :
    02/10/2015
    PARP1
    |
    bortezomib • veliparib (ABT-888)